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ABSTRACT 
Background: Hypothalamic-pituitary-adrenal (HPA) axis dysfunction in mood 
disorders is one of the most robust findings in biological psychiatry. However, 
considerable debate surrounds the nature of the core abnormality, its cause, 
consequences and treatment implications. 
Aims: To review the evidence for the role of HPA axis dysfunction in the 
pathophysiology of mood disorders with particular reference to corticosteroid 
receptor pathology. 
Methods: A selective review of the published literature in this field, focusing on 
human studies. 
Results: The nature of basal HPA axis dysregulation described in both manic and 
depressed bipolars appears to be similar to those described in MDD. But studies 
using the dexamethasone/ corticotropin releasing hormone (dex/CRH) test and 
dexamethasone suppression test (DST) have shown that HPA axis dysfunction is 
more prevalent in bipolar than in unipolar disorder. There is robust evidence for 
corticotropin releasing hormone (CRH) hyperdrive and glucocorticoid receptor 
(GR) dysfunction in mood disorders, with increasing evidence for disorders within 
^ the AVP system. 
Conclusion: HPA axis dysfunction is prevalent in patients with mood disorder, 
particularly those with psychotic disorders and bipolar affective disorder. This may 
be secondary to genetic factors, early life adversities or both. Dysfunction of GR 
may be the underlying abnormality and preliminary findings suggest that it is a 
potential target for novel therapies. 
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Mood disorders are common, often 
severe, life long; associated with significant 
handicap and disability and are associated 
with a high risk of death by both suicide 
(6-15%-(Goodwin, et al, 1990; Inskip, et al, 
1998) and physical disorders. It is still 
uncertain whether modern treatments have 
i substantially changed either the length of 
episodes or the number of relapses. 
Contemporary studies have found a life-
time prevalence of major depressive disor-
der of 4-19%. Traditionally episodes of 
unipolar
-depression were pictured as acute 
illnesses, self-limiting and lasting approxi-
mately 6-9 months from the time of onset 
to full recovery. A number of studies , 
however, show potential for great variation 
from this. Recovery may take much longer, 
or not occur at all. Moreover the risk of 
relapse and recurrence must be considered 
(Angst, 2000). At 5 years, 12% of unipolar 
depressed patients have still not recovered 
(Keller, et al, 1992) and by 10 years 7% have 
not recovered (Solomon, et al, 1997). 
For Bipolar I Disorder, the majority of 
epidemiological studies indicate lifetime 
prevalence rates of approximately 0.5-1% 
(Kessler, et al, 1994; Weissman, et al, 1996). 
Classically, bipolar disorder manifests as 
repeated periods of illness with complete 
recovery (Kraepelin, 1899). However, many 
patients have a poor outcome, a third suffer 
chronic symptoms and up to a quarter may 
develop rapid cycling disorder, where four 
or more episodes occur within a year. This 
poor clinical outcome is associated with 
significant disability in terms of social, 
marital and occupational dysfunction (Zarate, 
et al, 2000). Co-morbid illnesses include 
anxiety disorders, substance abuse and 
personality disorders (Kay, et al, 1999; 
McElroy, et al, 2001). A much wider, less 
well characterised bipolar spectrum also 
exists. This includes not only bipolar II 
disorder, characterised by episodes of de-
pression and hypomania but also less well 
recognised sub-syndromes combining hypo-
mania and minor depression or manic/ 
hypomanic symptoms alone. 
Hypothalamic-pituitary-adrenal (HPA) 
axis 
The hypothalamic-pituitary-adrenal (HPA) 
axis is a multifaceted regulatory system 
which integrates neuronal and endocrine 
function and consists of the hypothalamus, 
pituitary, adrenal cortex, and the associated 
regulatory inputs, releasing factors and 
hormones (see Fig. 1). The neurosecretory 
cells in the paraventricular nucleus (PVN) 
of the hypothalamus secrete corticotropin-
releasing hormone (CRH) and arginine 
vasopressin (AVP) into the microportal 
circulatory system of the pituitary stalk. 
They induce the release of adrenocortico-
tropic hormone (ACTH) from the anterior 
lobe of the pituitary into the systemic 
circulation. ACTH in turn promotes the 
release of the glucocorticoid - Cortisol from 
the zona fasciculate and zona reticularis of 
the adrenal cortex, and mineralocorticoid -
aldosterone from the zona glomerulosa of 
the adrenal cortex. 
The HPA axis has an extrinsic and 
intrinsic regulatory mechanism. The extrin-
sic regulatory inputs are received by the 
secretory cells in the PVN of the 
hypothalamus, from many brain regions, 
including amygdala, hippocampus and nu-
clei of the midbrain. In addition to these 
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there are excitatory and inhibitory afferents, 
including those containing 5-hydroxytryp-
tamine (5-HT), noradrenaline, acetylcholine, 
and both excitatory and inhibitory amino 
acids, Qones, et al, 1987). The intrinsic 
autoregulatory mechanism plays a crucial 
role in the regulation of the HPA axis. The 
glucocorticoid receptors (GR) play a key 
role in this feed back mechanism. The 
endogenous Cortisol, by binding to the GR 
in the HPA axis tissues and the hippocam-
pus, acts as a potent negative regulator of 
HPA activity (Sapolsky, et al, 1986). This 
autoregulatory role of endogenous Cortisol 
via the GR is crucial to the maintenance 
of the intrinsic homeostasis of the HPA 
axis Qacobson, et al, 1991; Sapolsky, et al, 
1986). 
The set point of pituitary feedback is 
determined by the hypothalamus acting 
through the hypothalamic releasing hor-
mones CRH and vasopressin. (Antoni, 1986; 
Vale, et al, 1983). Glucocorticoids act on 
both the pituitary corticotropes and the 
hypothalamic neurones that secrete CRH 
and vasopressin. A still higher level of 
feedback control is exerted by glucocorti-
coid responsive neurones in the hippocam-
pus that project to the hypothalamus and 
affect the activity of CRH hypophyseotropic 
neurones and in turn determine the set 
point of pituitary responsiveness to 
glucocorticoids (Sapolsky, et al, 1986). 
CORT (Cortisol in man, corticosterone in 
rats), in some respects the final product of 
the HPA axis, has both central and periph-
eral effects. It is lipid soluble and enter the 
brain through the blood-brain barrier (de 
Kloet, et al, 1993). CORT maintains basal 
activity of the HPA system. It also exerts 
rapid non genomic effects. CORT promotes 
co-ordination of circadian events, such as 
the sleep/wake cycle and food intake and 
is involved in processes underlying selective 
attention, integration of sensory informa-
tion and response selection. It facilitates an 
animals ability to cope with, adapt to, and 
recover from stress and promotes learning 
and memory processes (De Kloet, et al, 
1998). CORT acts on both type 1 - min-
eralocorticoid receptors (MR) and type 2 -
glucocorticoid receptors (GR) (De Kloet, et 
al, 1998). MR have a relatively restricted 
distribution, being particularly expressed in 
the hippocampus. GR are more widely 
distributed, have a 10-fold lower affinity for 
CORT and therefore their activation, in 
contrast to MR, varies widely across the 
diurnal range of CORT concentrations. MR , 
are saturated by basal levels of 
glucocorticoids, whereas GR are not satu-
rated under basal conditions, but approach 
saturation during peak phases of circadian 
rhythm and during stress. De Kloet and 
colleagues (De Kloet, et al, 1987; De Kloet, 
et al, 1998) have hypothesised that tonic 
influences of CORT are exerted via hippoc-
ampal MRs, while the additional occupancy 
of GRs with higher levels of CORT mediates 
feedback actions aimed to restore balances 
in homeostasis. 
Role of HPA axis in the 
Pathophysiology of mood disorders 
HPA axis dysfunction in mood disorders 
is suggested by the findings that 20-24% of 
patients with unipolar depression are 
hypercortisolaemic (Young, et al, 2001). 27-
43% of mood disorder patients have an 
abnormal DST response (Rush, et al, 1996) 
and 80% of unipolar depressed patients 
have an abnormal response to the dex/CRH 
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test (Heuser, et al, 1994). These findings 
raise a number of questions discussed 
below. 
I) What is the cause of HPA axis 
dysfunction? 
EARLY LIFE ADVERSITY 
Rodent studies show that early life ad-
versity such as maternal separation is asso-
ciated with persistent changes in the HPA 
axis, including alteration of hypothalamic 
CRH mRNA, median eminence CRH con-
tent and stress induced release in adult rats 
(Ladd, et al, 1996; Plotsky, et al, 1993) 
Studies in grown monkeys who were 
exposed as infants to adverse early rearing 
conditions showed that in comparison to 
monkeys reared by mothers foraging under 
predictable conditions, infant monkeys ex-
posed to early stress of being raised by 
mothers foraging under unpredictable con-
ditions exhibited persistently elevated cer-
ebrospinal fluid (CSF) concentrations of 
CRF. (Coplan, et al, 1996) These studies 
suggested that the increased risk of devel-
oping mood and anxiety disorders in adult-
hood that is consequent on childhood abuse 
and neglect and parental loss may be 
mediated by persistent alterations in CRH 
systems (Baker, et al, 1999; Coplan, et al, 
1996; Ladd, et al, 1996; Plotsky, et al, 1993). 
Non-depressed women with a history of 
childhood physical or sexual abuse have 
been shown to have an enhanced ACTH 
response to both the Trier social stress test 
(Heim, et al, 2000) and to CRH challenge 
(Heim, et al, 2001). The same group has 
shown that abused women without major 
depressive disorder exhibited greater than 
usual ACTH responses to CRH administra-
tion, whereas abused women with major 
depressive disorder and depressed women 
without early life stress demonstrated blunted 
ACTH responses. In the ACTH stimulation 
test, abused women without major depres-
sive disorder exhibited lower baseline and 
stimulated plasma Cortisol concentrations. 
Abused women with co-morbid depression 
more often suffered from posttraumatic 
stress disorder and reported more recent life 
stress than abused women without major 
depressive disorder. These findings suggest 
sensitisation of the anterior pituitary and 
counter-regulative adaptation of the adrenal 
cortex in abused women without major 
depressive disorder. On subsequent stress 
exposure, women with a history of child-
hood abuse may hypersecrete CRF, resulting 
in down-regulation of adenohypophyseal 
CRH receptors and symptoms of depres-
sion and anxiety (Heim, et al, 2001). 
GENETICS 
The Swedish twin registry study has 
shown that mood disorders are highly 
heritable. The authors estimated a heritabil-
ity of 64 to 83%. The same genetic and 
environmental factors appeared to influence 
liability to affective illness in men and 
women to the same degree, although women 
had a lower threshold of manifestation. The 
heritability of bipolar disorder has more 
recently been estimated at between 85 and 
89% (McGuffin, et al, 2003) and may share 
common genetic risk factors with schizo-
phrenia (Cardno, et al, 2002). The complex 
inheritance of bipolar disorder and the 
failure of multiple genome wide scans to 
detect major gene effects suggests that 
bipolar susceptibility loci probably have 
small to moderate effects. The Munich 
vulnerability study suggests that the familial 
association may be mediated via the HPA 
axis (Lauer, et al, 1998), however the her-
itability of bipolar disorder has not yet been 
convincingly shown to be mediated by 
genes acting on the HPA axis. 
2) Are some patients with mood 
disorder more likely than others to 
have an abnormal HPA axis? 
The HPA axis has been less well studied 
in bipolar disorder than in MDD. However, 
the nature of HPA axis dysregulation de-
scribed in both manic and depressed bipolars 
appears to be similar to those described in 
MDD. Abnormal neuroendocrine function 
in mood disorders has been most convinc-
ingly demonstrated using the dexametha-
sone/ corticotropin releasing hormone (dex/ 
CRH) test (Heuser, et al, 1994). Studies 
using this technique and the dexamethasone 
suppression test (DST) have shown that 
HPA axis dysfunction is more prevalent in 
bipolar than in unipolar disorder (Rush, et 
al, 1996; Rybakowski, et al, 1999). DST 
abnormalities in mixed mania (71%) and 
bipolar depression (25-60%) are more com-
mon than in major depressive disorder 
(37%-41%) (Rush, et al, 1996); (Nelson, 
1987). During mania, there is large variation 
in the results of different studies, with the 
rate of non-suppression being the same as 
in normal controls (Carroll, et al, 1976; 
Greden, et al, 1982) or equivalent to that 
seen in bipolar depression (Arana, et al, 
1983; Goodwin, 1984; Graham, et al, 1982). 
One explanation for this discrepancy in 
mania may be variation in the clinical state 
of patients sampled, e.g. the presence or 
absence of psychotic or depressive symp-
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3) What facets of HPA axis art 
abnormal? 
BASAL CORTISOL 
State dependent hypercortisolaemia asso-
ciated with depression were first demon-
strated by (Gibbons, 1964) and has since 
been repeatedly replicated although more 
recent studies suggest more moderate ab-
normalities than the original description 
(Dubrovsky, 1993); (Kirschbaum, et al, 1994; 
Rybakowski, et al, 1999; Schmider, et al, 
1995; Swann, et al, 1992; Whalley, et al, 
1989); (Vieta, et al, 1997; Watson, et al, 2001; 
Young, et al, 2001). A flattening of the 
diurnal Cortisol rhythm with an elevation in 
the afternoon trough appears to be a more 
robust finding fig. 3 (Cervantes, et al, 2001; 
Sachar, 1975). This abnormal rhythm can be 
expected to alter the activation of MR and 
GR. 
CRH HYPOTHESIS 
Professor Nemeroff's group has hypoth-
esised CRH overdrive (increased synthesis 
and release of CRH) to be central to the 
aetiopathophysiology of affective disorders 
(Nemeroff, 1988): Extra-hypothalamic CRH 
sites may play an important role in the 
mediation of behavioural response to stress 
and in the pathophysiology of anxiety and 
depression (Arborelius, et al, 1999). CRH 
immunoreactivity is present in the raphe 
nuclei and locus coeruleus (LQ which form 
the origin of the major serotonergic and 
noradrenergic projections to the forebrain 
(Valentino, et al, 1993). The amygdala, 
thought to mediate fear and anxiety (Davis, 
1992) is also innervated by CRH nerve 
terminals. Moreover, central administration 
of CRH to laboratory animals produces 
stress like effects including an increase in 
locomotor activity, an increased responsive-
ness to acoustic stimuli and reduced ex-
ploratory behaviour. It also produces de-
pression like effects, including diminished 
food intake, decreased sexual activity and 
disturbed sleep (Dunn, et al, 1990). The 
number, of CRH secreting neurones is 
increased in limbic areas of the brain 




concentration of CSF is increased 
(Nemeroff, et al, 1984). 
Gold and colleagues (Gold, et al, 1984) 
have shown that both depressed unipolar 
and bipolar patients have a blunted ACTH 
response to intravenously infused CRH, but 
a normal Cortisol response. The blunted 
ACTH response may be mediated by sub-
sensitivity of pituitary receptors to CRH, 
secondary to downregulation via CRH hyper-
drive or to homeostatic effects of elevated 
Cortisol levels. The anatomical correlate of 
this functional change is the reduced size 
of the pituitary gland that has been re-
corded in bipolar patients (Sassi, et al, 2001). 
The normal Cortisol response despite the 
reduced ACTH secretion is in keeping with 
rhe demonstration that depressed patients 
have an increased Cortisol response to ACTH 
(Amsterdam, et al, 1988; Amsterdam, et al, 
1983; Jaeckle, et al, 1987). Interestingly in 
Gold's study, in contrast to depressed pa-
tients, euthymic and manic patients had a 
normal ACTH response to CRH challenge 
(Gold, et al, 1984). Vieta and colleagues 
similarly demonstrated that bipolar patients 
who had been well for 6 months did not 
have a blunted ACTH response to CRH. 
Those patients with a more blunted re-
sponse were more likely to have a depressive 
relapse within 12 months and those with 
an exagerated response were at increased 
^. Blunted HPA and prolactin 
responses to 5-HT 
stimulation 
risk of subsequent mania (Vieta, et al, 1997; 
Vieta, et al, 1999). It is the CRH, rather than 
the CRH2 receptor that appears to convey 
anxiety and possibly, depression related 
signalling (Liebsch, et al, 1999). CRH, receptor 
deficient mice display less anxiety related 
behaviour (Timpl, et al, 1998). 
ARGININE VASOPRESSIN 
Like CRH, AVP is a hypothalamic hor-
mone. It acts synergistically with CRH to 
facilitate ACTH and hence Cortisol release. 
Physiologically, it appears to allow an acute 
stress response in conditions of chronic 
stress. Post-mortem studies of unipolar and 
bipolar patients who died by suicide show 
that AVP is increased in the PVN and that 
there is an increase in the number of CRH 
neurones co-expressing AVP (Purba, et al, 
1996; Raadsheer, et al, 1994). AVP release 
is suppressed by GR activation (Erkut, et al, 
1998). This suggests that the increase in 
plasma and CSF AVP levels which have 
been shown in some but not all studies in 
depression (Scott, et al, 1998), suggesting 
that AVP changes in patients may be sec-
ondary to GR dysfunction. This hypothesis 
is supported by our unpublished data show-
ing that AVP levels are greater in bipolar 
patients than controls after pre-treatment 
with the glucocorticoid, dexamethasone. 
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THE GLUCOCORTICOID 
RECEPTOR (GR) HYPOTHESIS 
It has been hypothesised that dysfunc-
tion of GR is the core underlying patho-
physiological abnormality in mood disor-
ders. See fig. 4 (McQuade, et al, 2000; 
Pariante, et al, 2001). Two post-mortem 
studies have shown low levels of GR 
mRNA in the frontal cortex and hippoc-
ampus in mood disorder patients (Lopez, 
et al, 2003; Webster, et al, 2002) Glucocor-
ticoid mediated negative feedback can be 
examined using the dexamethasone sup-
pression test (DST) and the dex/CRH test. 
An abnormal response on the DST and the 
dex/CRH test ie. non-supression of Cortisol 
secretion, suggests dysregulation of GR 
mediated feedback. GR knockout mice have 
impaired feedback regulation within the 
HPA axis, with elevated levels of plasma 
ACTH and corticosterone (Cole, et al, 1995; 
Cole, et al, 2001). A number of studies have 
examined GR number in peripheral blood 
mononuclear cells in affective disorder 
patients with largely inconsistent results 
(Pariante, et al, 2001). The CRH neurones 
in many brain areas are inhibited by GR 
activation. Therefore, it is suggested that the 
CRH overdrive, which has previously been 
hypothesised to be central to the 
aetiopathophysiology of affective disorders, 
could be a result of the underlying GR 
dysfunction. Reduced function of GR may 
be expected to exert greater effect on 
Cortisol level during the afternoon trough 
when the influence of other factors such 
as CRH and AVP is relatively less. It has 
not been satisfactorily shown experimen-
tally, but one can speculate that reduced GR 
function may give rise to the characteristic 




DHEA is an androgen secreted by the 
adrenal gland and to a lesser extend by the 
ovaries and testes. It can also be converted 
in to other steroid hormones such as 
oestrogen and testesterone and exists in 
both a free, and sulphated (DHEA-S) form. 
Animal studies show that DHEA counter-
acts the deleterious effects of corticosteroids 
on long-term potentiation, a neurophysi-
ological correlate of learning and memory 
(Kaminska, et al, 2000). DHEA levels regu-
late glucocorticoid action in the brain. The 
ratio of Cortisol to DHEA therefore reflects 
the degree of 'functional' hypercortisolaemia 
and has recently been shown to be en-
hanced in a drug free population of patients 
with major depressive disorder (Young, et 
al, 2002a). 
4) Is HPA axis dysfunction a cause 
or consequence of affective 
disorder? 
Two separate groups have demonstrated 
that bipolar patients when manic or de-
pressed show abnormalities on the dex/ 
CRH test (Rybakowski, etal, 1999; Schmider, 
et al, 1995). They both re-examined the 
patients on symptomatic recovery and 
showed that the Cortisol response, whilst 
partially normalising still remained signifi-
cantly different from the response of healthy 
controls (Rybakowski, et al, 1999; Schmider, 
et al, 1995). Similarly, bipolar patients with 
a stringent prospective diagnosis of euthymia 
have been shown to have an abnormally 
enhanced Cortisol response using the same 
test . This suggests that this measure of 
HPA axis dysfunction may be a trait abnor-
mality and as such may potentially represent 
a vulnerability factor for bipolar disorder. In 
a longitudinal follow up study, (Goodwin, 
1984) found that individual's DST responses 
were consistent over time, regardless of 
their clinical state, providing further support 
for the hypothesis that the HPA axis dys-
function is a trait abnormality of bipolar 
disorder. This has been further addressed 
by the Munich vulnerability studv (Lauer, et 
al, 1998), in which 32% of healthy volun-
teers with a family history of mood disorder 
had an abnormal response to the dex/CRH 
test. Unfortunately, the high drop out in this 
study will make it difficult to determine if 
these relatives have an increased risk of 
developing bipolar disorder (Modell, et al, 
1998). However, researchers in the UK have 
demonstrated that morning salivary Cortisol 
concentrations are a risk factor for subse-
quent development of unipolar major de-
pressive disorder (Harris, et al, 2000). 
CONSEQUENCES OF HPA 
AXIS DYSFUNCTION 
In recent years it has become clear that, 
in addition to effects on metabolic and 
inflammatory processes, corticosteroids also 
play an extensive modulatory role in 
neurotransmission. Studies in experimental 
animals have indicated that expression and 
function of neurotransmitter receptors and 
enzymes, long-term potentiation and even 
cell survival are all influenced by 
corticosteroids. Glucocorticoid therapy has 
been shown to be associated with a range 
of psychopathology including depression, 
euphoria, mood lability, cognitive impair-
ment and psychosis (Baker, et al, 1999). It 
is unsurprising, therefore, that behavioural 
indices of neurotransmitter function, such 
as mood and cognition, are also influenced 
by corticosteroid manipulations. 
MONOAMINE SYSTEMS 
Disorders of the serotonin system have 
been thought to be of aetiological and 
therapeutic importance in depression since 
the 1960's. A number of strands of evi-
dence converge to suggest a pathophysi-
ological role for reduced transmission 
through post synaptic 5-HT|A receptors in 
depression. Chronic elevation of 
corticosteroids reduces post synaptic 5-
HT|A receptor number, an effect which may 
promote depression (McAllister-Williams, et 
al, 1998). In contrast, acutely elevated plasma 
Cortisol levels, induced by acute stress or 
administration of hydrocortisone reduces 
somatodendritic rather than post-synaptic 5-
HT1A receptor function, thereby facilitating 
5-HTM neurotransmission in an antidepres-
sant like way (Laaris, et al, 1999; Young, et 
al, 1994a; Young, et al, 1994b) and has been 
shown to exert a mood elevating effect 
(DeBattista, et al, 2000). Our group has 
shown that flattening the rhythm without 
increasing the 24 hour output results in 
reduced 5HT|A neurotransmission (Leitch, et 
al, 2003). 
Pre-clinical studies have also shown that 
corticosteroids increase dopamine 
neurotransmission. This mechanism has been 
hypothesised to be pathophysiological im-
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portance in mania, psychotic depression and 
substance misuse (Schatzberg, et al, 1985) 
ENDOCRINE DISORDERS 
Cushing's disease in which ACTH and 
hence Cortisol are increased is associated 
with depression in 70% of patients. Memory 
disturbances, in particular, biasing toward 
negative contents, overlapping sleep abnor-
malities (marked reduction of stages 3 and 
4), increased fatigue and loss of energy, 
attentional deficits and irritability, are just 
part of the common symptoms presented 
by patients with both Cushing's disorder 
and depression. All of these behavioural 
manifestations are known to be affected by 
adrenal steroid hormones (Dubrovsky, 1993). 
Whilst antidepressants offer some benefit, 
controlling Cortisol levels appears to be the 
most effective treatment. 
Addison's disease, in which Cortisol syn-
thesis is defective, is also associated with 
high rates of psychiatric disorder, which 
improve on successful steroid replacement. 
A number of chronic medical diseases such 
as multiple sclerosis are also associated with 
both elevated Cortisol levels and high rates 
of psychopathology. 
NEUROGENESIS 
Mood disorders are associated with a loss 
of brain cells, particularly glia and schizo-
phrenia is associated with neuronal atrophy. 
Throughout adult life new neurones con-
tinue to be made in brain areas including 
the hippocampus and olfactory bulb. 
Corticosteroids have an important role in 
mediating neurogenesis and survival of new 
cells. Although difficult to study in humans, 
it has been hypothesised that reduced 
neurogenesis is causative in depression and 
that the therapeutic effect of antidepres-
sants is mediated by an enhancement of 
new cell production and survival, perhaps 
via effects on the HPA axis. Evidence for 
this includes the demonstration that stress 
reduces neurogenesis and causes learned 
helplessness in rodents, effects that are 
prevented by chronic treatment with an 
antidepressant (Gould, rt al, 2000). 
NEUROCOGNITIVE 
IMPAIRMENT 
Corticosteroids are essential for cognitive 
performance. MR appear to promote reac-
tivity in novel situations whereas GR are 
involved in consolidation of learned infor-
mation. It may therefore seem paradoxical 
mat disorders (including Cushing's disease 
and severe mood disorders) and experimen-
tal conditions in which endogenous or 
exogenous corticosteroids are elevated ei-
ther acutely or chronically are associated 
with a significant degree of cognitive im-
pairment. It appears that the effects of 
corticosteroids on cognition can become 
maladaptive when the activity of the two 
types of receptor becomes either persist-
endy unbalanced or out of context with the 
situation (De Kloet, et al, 1998). 
Sapolsky has suggested a causal link 
between chronic hypercortisolaemia, hip-
pocampal atrophy and neurocognitive im-
pairment (Sapolsky, et al, 1986). Evidence 
for this is growing and includes studies in 
experimental animals which has shown that 
chronic administration of corticosteroids 
results in deficits in learning and memory 
(Lupien, et al, 1997; White-Gbadebo, et al, 
1993) and atrophy of neurones in the 
hippocampal formation. Chronic adminis-
tration of corticosteroids in healthy humans 
is also associated with cognitive impairment 
(Young, et al, 1999). Furthermore, the 
cognitive tests which are most affected are 
dependent on intact function of frontal-
hippocampal activity. Studies comparing 
mood disorder patients with normal con-
trols suggest that the cognitive deficits in 
patients are irreversible and suggest long 
term hypercortisolaemia-induced damage to 
crucial neuronal circuits (Ferrier, et al, 1999). 
The findings that Cortisol levels after pre-
treatment with dexamethasone correlate with 
neurocognitive impairment and tests of 
executive function in recovered bipolar 
patients suggest that the causal link may be 
driven by GR dysfunction rather than sim-
ple hypercortisolaemia (Watson, et al, 2002). 
An early re-establishment of normal HPA 
activity in mood disorders before perma-
nent deficits in cognitive function occur may 
therefore be an important therapeutic goal. 
What are the treatment implications? 
CURRENTLY AVAILABLE 
TREATMENTS 
Currendy available psychotropic drugs 
may act via the HPA axis. Thus, (Heuser, 
et al, 1996) and colleagues have shown that 
successful treatment of unipolar depression 
with amitryptiline is associated with a re-
duction in the Cortisol response to the dex/ 
CRH test. This may be mediated by nor-
malisation of dysfunctional corticosteroid 
receptors (McQuade, et al, 2000). It is of 
interest that whilst some drugs such as 
lithium which appear to act on GR, stabilise 
mood in bipolar disorder, others such as the 
tricyclics increase cycle frequency rate and 
can induce mania (McQuade, et al, 2000; 
Wehr, et al, 1987). 




Antiglucocorticoid treatment, which is 
aimed at lowering Cortisol levels, has been 
investigated using ketoconazole, 
ammoglutethirnide or metyrapone in several 
studies in MDD and one in bipolar disorder. 
The majority of the trials have been open 
studies but there have also been two 
randomised-controlled trials. Side-effects are 
common but the data suggests that in the 
patients who are able to tolerate the treat-
ment there is an association with improve-
ment in mood, particularly in those patients 
with previously demonstrated 
hypercortisolaemia (Brown, et al, 2001). The 
equivocal results may be explained by the 
mechanism of action of antiglucocorticoids, 
which exert effects on the steroid biosyn-
thesis pathway. They therefore reduce the 
synthesis of Cortisol but also exert profound 
effects on the synthesis of other adrenal 
steroids. Cortisol synthesis inhibitors are 
unlikely to become routine drugs in the 
treatment of bipolar disorder, largely be-
cause of side effects and drug interactions. 
However, their efficacy in some patients 
supports the use of other pharmacological 
interventions that target specific sites in the 
HPA axis. 
(10) GLUCOCORTICOID RECEPTOR DYSFUNCTION 
RHYTHM 
The biochemical, cognitive or mood 
effects of the flattened Cortisol rhythm seen 
in bipolar disorder patients has not yet been 
examined in man, however it is possible to 
speculate that modulation of the Cortisol 
rhythm of mood disorder patients may have 
effects on mood and cognition and may 
represent a novel therapeutic approach. 
CRH-I RECEPTOR 
ANTAGONIST 
The CRH, receptor antagonist R121919 
has been used in an open treatment trial 
of 24 patients with major depression and 
appears to be safe and well tolerated and 
is associated with a reduction in anxiety and 
depression (Zobel, et al, 2000). 
GR ANTAGONISTS 
The GR antagonist mifepristone has 
been shown to reduce depressive symptoms 
in open trials of patients with psychotic and 
non-psychotic depression (Belanoff, et al, 
2001), to reduce depressive and psychotic 
symptoms in Cushing's syndrome (Nieman, 
et al, 1985; van der Lely, et al, 1991) and 
improve cognitive performance in Alzheim-
er's disease (Pomara, et al, 2002). It may 
exert acute therapeutic effect by blocking 
GR receptors thereby creating a "functional 
hypocortisolaemia". Additionally, it is hy-
pothesised that prolonged blockade may 
increase corticosteroid receptor function or 
number and reset the homeostatic set point 
thereby restoring the characteristic diurnal 
rhythm and potentially offering long-term 
benefit. Its use in bipolar disorder is being 
examined in a placebo controlled cross-over 
trial by our group and preliminary results 
presented at the society of biological psy-
chiatry annual meeting in Philadelphia sug-
gest an association with an improvement in 
executive function (Young, et al, 2002b). 
Org 34517 has been shown in vitro, in 
animals and humans to be a selective 
glucocorticoid receptor antagonist. A 
multicentre, randomised, double-blind, 
paroxetine controlled study of Org34517 in 
patients with major depressive has shown 
that it is well tolerated during the 4 weeks 
treatment period in the dose range of 150-
600 mg (Hoyberg, et al, 2002). Although it 
was not shown to be significantly more 
effective than 20-40 mg paroxetine in sub-
jects with moderate to severe MDD, when 
focusing on patients with detectable HPA 
disturbances, a clear indication was found 
for stronger efficacy of the low dose (150-
300mg) Org regimen as compared with 
paroxetine. This effect was more pronounced 
in DST-nonsuppressors and during the first 
two weeks of treatment. High dose 
Org34517 increased Cortisol, DHEA-s and 
testosterone levels, which is evidence for a 
detectable degree of GR-blockade. Subjects 
who seemed to benefit from treatment with 
low dose Org34517 did not show a detect-
able increase in Cortisol and other HPA 
driven hormones levels during the first 
weeks of treatment. 
AVPIB RECEPTOR 
ANTAGONISTS 
The AVP|b receptor antagonists, 
SSR149415 and d(CH2)Tyr(Et)VAVP 
(Griebel, et al, 2002; Liebsch, et al, 1996) 
have been shown to have anxiolytic prop-
erties in animal studies and represent an 
exciting potential pharmacological strategy 
for the treatment of mood disorders. 
DEHYDROEPIANDROSTERONE 
(DHEA) 
Improvements in cognition have been 
observed after administration of DHEA to 
middle-aged and elderly depressed patients 
(Wolkowitz, et al, 1997) and the antidepres-
sant actions of DHEA have recently been 
demonstrated in a small randomised con-
trolled trial in depression (Wolkowitz, et al, 
1999). Case reports of mania induced by 
massive DHEA doses (Dean, 2000; Kline, 
et al, 1999; Markowitz, et al, 1999) suggest 
the need for caution, however DHEA 
administration represents an exciting poten-
tial novel therapeutic approach in bipolar 
disorder. 
CONCLUSIONS 
HPA axis dysfunction is prevalent in 
patients with mood disorder, particularly the 
psychotic disorders and bipolar affective 
disorder. It has implications in the patho-
physiology and cognitive impairment in 
mood disorders. It is more overt when 
patients are unwell, but still present in 
euthymia and present in a third of appar-
ently healthy patients with genetic loading. 
The HPA axis dysfunction may be second-
ary to genetic factors or early life adversities. 
Elevated Cortisol levels are not consistently 
shown but tests which incorporate exami-
nation of glucocorticoid receptor function 
reveal higher rates of abnormality. It ap-
pears that dysfunction of GR may be the 
underlying abnormality in mood disorders, 
and preliminary findings suggest that it is 
a potential target for novel therapies. 
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